Results 251 to 260 of about 114,558 (301)

Integrative preclinical strategy for pharmacokinetic profiling and candidate selection of 3-hydroxypropanamidines: a promising antimalarial class. [PDF]

Malar J
Moritz A, Hirn-Derksen B, Klein S, Held J, Wittlin S, Rottmann M, Kurz T, Burckhardt BB.   +7 more
europepmc   +1 more source

PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson's disease models. [PDF]

Brain
Albornoz EA, Mardon K, Bhalla R, Kumar V, Stimson DHR, Cowin G, Cui CS, Butler MS, Pelingon R, Gordon R, Coll RC, Schroder K, Halai R, MacLeod AM, Matthews K, Robertson AAB, Cooper MA, Woodruff TM.   +17 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Preclinical pharmacokinetics of statins

Methods and Findings in Experimental and Clinical Pharmacology, 2002
This review summarizes the pharmacokinetic properties of HMG-CoA reductase inhibitors (or statins) reported in animals. Lovastatin and simvastatin are administered as lactone prodrugs in contrast to other statins, which are generally formulated in the pharmacological active hydroxy acid form.
R F, Reinoso, A, Sánchez Navarro, M J, García, J R, Prous   +3 more
openaire   +2 more sources

Clinical and Preclinical Pharmacokinetics of Raltitrexed

Clinical Pharmacokinetics, 2000
Raltitrexed is a specific, folate-based inhibitor of thymidylate synthase with activity in advanced colorectal cancer comparable with that of fluorouracil (5-fluorouracil) plus folinic acid. Its activity is enhanced by rapid cellular entry and polyglutamation, with the polyglutamated derivatives having approximately 100-fold greater inhibitory potency ...
S J, Clarke, P J, Beale, L P, Rivory
openaire   +2 more sources

Preclinical pharmacokinetics of paclitaxel and docetaxel

Anti-Cancer Drugs, 1998
The taxanes paclitaxel and docetaxel represent a novel class of antineoplastic agents. A major problem of both drugs is their low aqueous solubility and the design of suitable formulations has been a difficult step in the process of therapeutic development.
Sparreboom, A., van Tellingen, O., Nooijen, W.J., Beijnen, J.H.   +3 more
openaire   +3 more sources

Preclinical pharmacokinetics of radiolabelled hyaluronan

Pharmacological Reports, 2012
Hyaluronan (HYA) is a high molecular weight glucosaminoglycan with a great perspective for medical applications. Because HYA is widespread in the body, it is difficult to determine the fate of exogenously administered HYA.In this study, HYAof different molecular weights (0.1-1 MDa) was labelled with (99m)Tc, and the distribution profiles were ...
Milan, Laznicek, Alice, Laznickova, Dagmar, Cozikova, Vladimir, Velebny   +3 more
openaire   +2 more sources

Preclinical pharmacokinetics and antitumor activity of imexon

Investigational New Drugs, 1995
Imexon is an aziridine compound originally studied for immune-enhancing effects on lymphocytes. The drug was well-tolerated in humans and was shown to be active in a variety of animal tumor models. Recently, imexon has demonstrated antitumor activity in human multiple myeloma cell lines in vitro.
R T, Dorr, J D, Liddil, M K, Klein, E M, Hersh   +3 more
openaire   +2 more sources

Preclinical Pharmacokinetics of Triptolide: A Potential Antitumor Drug

Current Drug Metabolism, 2019
Background:Triptolide, a bioactive component in Tripterygium wilfordii extracts, possess strong antiproliferative activity on all 60-National Cancer Institute (NCI) cancer cell lines. However, the widespread use of triptolide in the clinical practice is greatly limited for its multi-organ toxicity and narrow therapeutic window.
Wei Song, Yong Chen, Zhihong Peng
exaly   +3 more sources

Pharmacokinetics, Metabolites, and Preclinical Safety of Vinflunine

Seminars in Oncology, 2008
The novel microtubule inhibitor, vinflunine, has a unique mechanism of action that differs from other members of the vinca alkaloid class in terms of tubulin-binding affinity, microtubule dynamics, spiral formation, and intracellular accumulation. Vinflunine has shown significant activity in vivo, which involves its antimitotic, antiangiogenic, and ...
Sharon, Lobert, Christian, Puozzo
openaire   +2 more sources